## ELV: Elevance Health, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.00 indicates fundamental undervaluation. Caution: momentum weakening (-5.4% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($324.87)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 9
- **Sentiment:** Neutral (Bullish: 0, Bearish: 4)

**1. What Does the Market Think About Elevance Health Inc?**
- Source: Sahm | 20251223T090738 | Somewhat-Bullish | Relevance: 100%
- Elevance Health Inc.'s (NYSE: ELV) short interest has decreased by 3.85% since its last report, with 3.88 million shares sold short, representing 1.75% of available shares. This decline in short interest suggests a potentially more bullish market sentiment toward the stock. Compared to its peers, Elevance Health Inc. has less short interest, averaging 1.75% versus the peer group average of 6.63%.

**2. How to listen to Elevance Health’s 2025 earnings call live**
- Source: Stock Titan | 20251222T213224 | Neutral | Relevance: 100%
- Elevance Health (NYSE: ELV) will release its fourth quarter and full-year 2025 financial results on January 28, 2026, at 6:00 a.m. EST, followed by a conference call at 8:30 a.m. EST. Investors can access the call via phone or live webcast, with a replay available until February 27, 2026. The company provides details for both domestic and international access to the earnings call and webcast.

**3. Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elevance Health, Inc. (ELV) and Encourages Shareholders to Learn More About the Investigation**
- Source: ValleyCentral.com | 20251221T170750 | Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Elevance Health, Inc. (NYSE: ELV) to determine if the company and its officers engaged in corporate wrongdoing. The firm is encouraging investors who purchased Elevance securities before April 18, 2024, and still hold them, to learn more and assist in the investigation. The firm represents investors on a contingency fee basis in securities fraud class actions and shareholder derivative suits.

**4. What You Need To Know Ahead of Elevance Health’s Earnings Release**
- Source: FinancialContent | 20251223T140826 | Neutral | Relevance: 100%
- Elevance Health (ELV) is set to release its Q4 2025 earnings at the end of January, with analysts forecasting a nearly 17% year-over-year EPS decline to $3.19. Despite a mixed earnings track record and shares underperforming the broader market, Wall Street maintains a "Moderate Buy" consensus, anticipating a 12.6% upside from current levels. The company's Q3 2025 results beat expectations, driven by strong revenue growth and effective management strategies despite margin pressures.

**5. Elevance Health, Inc. $ELV Shares Sold by Voya Investment Management LLC**
- Source: MarketBeat | 20251223T133957 | Somewhat-Bullish | Relevance: 100%
- Voya Investment Management LLC significantly reduced its stake in Elevance Health, Inc. (NYSE:ELV) by 34.7% during Q3, selling 28,446 shares. Despite this, Elevance Health reported strong Q3 earnings, beating analyst estimates with an EPS of $6.03 and revenues of $50.09 billion, representing a 12% year-over-year increase. The company maintains a "Moderate Buy" consensus rating from analysts, with an average price target of $396.21.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-19 | Deutsche Bank | $320 | $332 | -4% |
| 2025-12-18 | Morgan Stanley | $352 | $359 | -2% |
| 2025-11-26 | TD Cowen | $400 | $380 | +5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-19 | Deutsche Bank | down | Hold |
| 2025-12-18 | Morgan Stanley | main | Equal-Weight |
| 2025-11-26 | TD Cowen | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.98M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 40.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.3% (+0.6%)
- Blackrock Inc.: 9.2% (+0.6%)
- State Street Corpora: 4.7% (-2.1%)
- Wellington Managemen: 3.0% (+4.8%)
- Price (T.Rowe) Assoc: 2.6% (-27.8%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-5.4% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.00 suggests fair value with growth premium. Analyst sentiment negative (2 target cuts vs 1 raises). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $77.3B |
| Beta | 0.53 |
| 52W Range | $273.71 - $458.75 |
| Short Interest | 1.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.00 |
| Forward P/E | 12.7 |
| Current P/E | 11.4 |
| YoY Growth | -10.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 5.2% to -0.2% (-5.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.2pp (needs >4.0% for momentum thesis). Below SMA200 (0.96x), long-term trend not supportive. RSI neutral at 54. OFD pattern: +DBL (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.19% (CS: 54) | Neutral |
| RSI_14 | 53.5 | Neutral |
| MACD Histogram | -0.26 | Bearish |
| vs SMA20 | 1.007x | Above |
| vs SMA50 | 1.026x | Above |
| vs SMA200 | 0.965x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $343.27
- **Stop Loss:** $324.87 (5.4% risk)
- **Target:** $380.07 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 65
- **Position Value:** $22,312.55
- **Portfolio %:** 22.31%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-01-22 (Est: $3.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.94 | $6.03 | +22.0% |
| 2025Q2 | $8.96 | $8.84 | -1.4% |
| 2025Q1 | $11.48 | $11.97 | +4.3% |
| 2024Q4 | $3.85 | $3.84 | -0.3% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*